ArticleBMC health services research2013
A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
Article in BMC health services research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Influencing Factors of Generic Prescribing Behavior of Physicians: A Structural Equation Model Based on the Theory of Planned Behavior.Risk management and healthcare policy · 2024Article
- Self-Medication Behaviors of Chinese Residents and Consideration Related to Drug Prices and Medical Insurance Reimbursement When Self-Medicating: A Cross-Sectional Study.International journal of environmental research and public health · 2022Article
- Improving access to medicines by popularising generics: a study of 'India's People's Medicine' scheme in two districts of Maharashtra.BMC health services research · 2022Article
- Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China.Frontiers in pharmacology · 2022Article
- The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.Frontiers in pharmacology · 2022Article
- Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China.Frontiers in pharmacology · 2021Article
- Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria.BMC health services research · 2019Article
- A review of promoting access to medicines in China - problems and recommendations.BMC health services research · 2018Review
- Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis.Journal of diabetes investigation · 2018Article
- Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.BMC health services research · 2016Article
- Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future.International journal of clinical pharmacy · 2015Article
- Prescribing efficiency of proton pump inhibitors in China: influence and future directions.BMC health services research · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeveloped countries use generic competition to contain pharmaceutical expenditure. China, as a developing and transitional country, has not yet deemed an increase in the use of generic products as important; otherwise, much effort has been made to decrease the drug prices. This paper aims to explore dynamically the price and use comparison of generic and originator drugs in China, and estimate the potential savings of patients from switching originator drugs to generics.
methodsA typical hospital in Chongqing, China, was selected to examine the price and use comparisons of 12 cardiovascular drugs from 2006 to 2011.
resultsThe market share of the 12 generic medicines studied in this paper was 34.37% for volume and 31.33% for value in the second half of 2011. The price ratio of generic to originator drugs was between 0.34 and 0.98, and the volume price index of originators to generics was 1.63. The potential savings of patients from switching originator drugs to generics is 65%.
conclusionThe market share of the generics was lowering and the weighted mean price kept increasing in face of the strict price control. Under the background of hospitals both prescribing and dispensing medicines, China's comprehensive healthcare policy makers should take measures from supply and demand sides to promote the consumption of generic medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.